ALLO Allogene Therapeutics Forecast, Technical & Fundamental Analysis
Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases... Show more
ALLO is expected to report earnings to fall 1.00% to -17 cents per share on August 05
Q2'26
Est.
$-0.18
Q1'26
Beat
by $0.01
Q4'25
Beat
by $0.06
Q3'25
Beat
by $0.03
Q2'25
Beat
by $0.04
The last earnings report on May 13 showed earnings per share of -18 cents, beating the estimate of -18 cents. With 9.05M shares outstanding, the current market capitalization sits at 707.57M.
A.I. Advisor
published General Information
General Information
a developer of allogeneic chimeric antigen receptor therapy
A.I.dvisor indicates that over the last year, ALLO has been loosely correlated with AXON. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if ALLO jumps, then AXON could also see price increases.
The Moving Average Convergence Divergence (MACD) for ALLO turned positive on May 27, 2026. Looking at past instances where ALLO's MACD turned positive, the stock continued to rise in of 51 cases over the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ALLO's RSI Indicator exited the oversold zone, of 38 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Momentum Indicator moved above the 0 level on May 29, 2026. You may want to consider a long position or call options on ALLO as a result. In of 87 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ALLO advanced for three days, in of 228 cases, the price rose further within the following month. The odds of a continued upward trend are .
ALLO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 61 cases where ALLO's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
The 10-day moving average for ALLO crossed bearishly below the 50-day moving average on April 27, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALLO declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for ALLO entered a downward trend on May 29, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ALLO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.469) is normal, around the industry mean (21.430). P/E Ratio (0.000) is within average values for comparable stocks, (35.359). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.649). ALLO has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.039). ALLO's P/S Ratio (10000.000) is very high in comparison to the industry average of (362.782).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALLO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
